Global Information
회사소개 | 문의 | 비교리스트

척삭종 치료제 시장 : 약제 클래스별, 치료 종류별, 최종사용자별, 지역별 - 규모, 점유율, 전망, 기회 분석(2020-2027년)

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

리서치사 Coherent Market Insights
발행일 2020년 07월 상품 코드 948417
페이지 정보 영문
가격
US $ 4,500 ₩ 5,391,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,387,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,982,000 PPT Turned PDF (Enterprise User License)


척삭종 치료제 시장 : 약제 클래스별, 치료 종류별, 최종사용자별, 지역별 - 규모, 점유율, 전망, 기회 분석(2020-2027년) Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
발행일 : 2020년 07월 페이지 정보 : 영문

척삭종은 많은 치료상 제한이 있는 희귀암입니다. 세계의 척삭종 치료제 시장은 첨단 치료법을 개발하기 위한 주요 시장 진출 기업의 연구개발 활동 증가에 의해 예측기간 중 성장이 기대되고 있습니다.

세계의 척삭종 치료제 시장에 대해 조사했으며, 시장 기회와 동향, 성장 촉진요인 및 억제요인, 약제 종류·치료 종류·최종사용자·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 목적과 가정

제2장 시장 전망

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약
    • 시장 내역 : 약제 클래스별
    • 시장 내역 : 치료 종류별
    • 시장 내역 : 최종사용자별
    • 시장 내역 : 지역별
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
  • 영향 분석
  • 주요 발전
  • PEST 분석

제4장 COVID-19 팬데믹의 영향

  • 영향 조사
  • COVID-19 팬데믹 이전 시장 시나리오
  • COVID-19 팬데믹 이후 시장 시나리오
  • COVID-19에 대한 정부 조치

제1장 시장 분석 : 약제 클래스별

  • 서론
  • 대사길항제
  • 안트라사이클린
  • VEGFR 억제제
  • EGFR 억제제
  • 기타

제2장 시장 분석 : 치료 종류별

  • 서론
  • 화학요법
  • 표적요법
  • 방사선요법
  • 기타

제3장 시장 분석 : 최종사용자별

  • 서론
  • 병원
  • 클리닉
  • 종양 센터
  • 기타

제4장 시장 분석 : 지역별

  • 서론
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제5장 경쟁 상황

  • 히트맵 분석
  • 시장 점유율 분석
    • GlaxoSmithKline Plc
    • Bavarian Nordic
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Sanofi SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Amgen, Inc.
    • Bristol-Myers Squibb and Company
    • Novartis International AG
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Mylan N.V.
  • 애널리스트의 견해

제6장 섹션

KSM 20.07.29

Title:
Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Chordoma is a rare cancer along with many treatment limitations. The tumor grows slowly in the bones of skull and spine when an individual is suffering from chordoma. Around half of all chordomas occur at the sacrum (base of the spine), approximately one third occur in the occiput (base of the skull), while rest of the chordomas occur in the cervical (neck), thoracic (upper back) or lumbar (lower back) vertebrae of the spine. A chordoma growth in the spine region may cause weakness, pain or numbness in the back, legs or arms. An occipital chordoma (chordoma at the base of skull) may lead to diplopia (double vision) and headaches while coccygeal chordoma (chordoma occurring in the tailbone) may result in a large lump, which may cause problems with bladder or bowel function.

Although chordoma is a rare type of cancer, increasing research and development activities for its treatment is likely to drive growth of the chordoma disease therapeutics market over the forecast period.

Market Dynamics

The increasing number of research and development activities by key players operating in the market, in order to develop advanced treatment for chordoma, is expected to propel the market growth over the forecast period. For instance, in June 2018, Boehringer Ingelheim, a pharmaceutical company, initiated phase 2 clinical trial in collaboration with the Chordoma Foundation, a non-profit organization. The purpose of the trial was to evaluate the safety and efficacy of Afatinib, a tyrosine kinase inhibitor, as first line or later line treatment in advanced chordoma.

Key features of the study:

  • This report provides in-depth analysis of the global chordoma disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chordoma disease therapeutics market based on the following parameters - company overview, financial performance, Drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy's Laboratories Ltd., and Mylan N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global chordoma disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chordoma disease therapeutics market

Detailed Segmentation:

  • Global Chordoma Disease Therapeutics Market, By Drug Class:
    • Antimetabolites
    • Anthracycline
    • VEGFR Inhibitors
    • EGFR Inhibitor
    • Others
  • Global Chordoma Disease Therapeutics Market, By Treatment Type:
    • Chemotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Others
  • Global Chordoma Disease Therapeutics Market, By End User:
    • Hospitals
    • Clinics
    • Oncology Centers
    • Others
  • Global Chordoma Disease Therapeutics Market, By Region:
    • North America
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bavarian Nordic A/S
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Sanofi SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Amgen, Inc.
    • Bristol-Myers Squibb and Company
    • Novartis International AG
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Mylan N.V.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Treatment Type
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • PEST Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

  • Impact assessment
  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Government measures to combat COVID-19

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Anthracycline
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • VEGFR Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • EGFR Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Radiation Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Oncology Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

5. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • GlaxoSmithKline Plc
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bavarian Nordic
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Boehringer Ingelheim International GmbH
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sanofi SA
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Astellas Pharma Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AstraZeneca plc
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amgen, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol-Myers Squibb and Company
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis International AG
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bayer AG
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan N.V.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

6. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q